Androgens, progestins and tamoxifen induce PSA production in the breast cancer cell line T-47D
β Scribed by E.P. Diamandis; Y. He; L. Grass
- Publisher
- Elsevier Science
- Year
- 1994
- Tongue
- English
- Weight
- 124 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0009-9120
No coin nor oath required. For personal study only.
β¦ Synopsis
CHEMISTS
2h to complete, is precise (CV's<I0%) and highly sensitive, with a detection limit of <0.05 pg/L. Comparison with an enzymatic CK-BB assay for 166 breast tumor cytosols (determination of CK-B subunit after immunoinhibition of CK-M subunit) gave the following equation: y (TR-FIA method) = 0.71 x (enzymatic method) + 5,8, r = 0.83. Crossreactivity of the CK-BB TR-FIA assay by CK-MM was not detectable at concentrations as high as 1000 pg/L. The cross-reactivity of CK-MB isoenzyme was 5% at 100 pg/L of CK-MB. The method was used to measure CK-BB activity in 166 breast tumor cytosols which were also measured for (ER) and progesterone (PR) receptors. Using a cutoff value of 10 fmol/mg protein for the receptors and 26 pg/L for CK-BB, we examined the possible association between receptors and CK-BB. We found a strong association between CK-BB and ER (P=0.001, chi-square test) and a weak association between CK-BB and PR (P=0.054). We conclude that CK-BB production by breast tumors is mediated by the action of the estrogen receptor.
π SIMILAR VOLUMES
## Abstract Steroid regulation of 17Ξ²βhydroxysteroid dehydrogenase (17βHSD) was studied in the Tβ47D human breastβcancer cell line, using a radioimmunoassay. In addition, 3 mRNA species (2.4, 1.4, and 0.9 kb) specific for the enzyme were shown to be present in these cells. All the synthetic progest
In many cancer cell lines, including breast, prostate, lung, brain, head and neck, retina, and the gastrointestinal tract, opioids decrease cell proliferation in a dose-dependent and reversible manner. Opioid and/or other neuropeptide receptors mediate this decrease. We report that only the steroid-
Since estrogens play a predominant role in the development and growth of human breast cancer, antiestrogens represent a logical approach to the treatment of this disease. The present study compares the effects of the novel nonsteroidal anti-estrogen EM-800 and related compounds with those of a serie